Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Methocarbamol Tablets, Usp, 750 Mg
Generic Name
Methocarbamol
Active Ingredient
MethocarbamolCategory
Muscle Relaxant [EPC]
Variants
4
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 750 mg/1 | TABLET, FILM COATED | ORAL | 63561-0174 |
| 750 mg/1 | TABLET, FILM COATED | ORAL | 72789-521 |
| 750 mg/1 | TABLET, FILM COATED | ORAL |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Methocarbamol Tablets, Usp, 750 Mg, you must consult a qualified healthcare professional.
| 750 mg/1 | TABLET, FILM COATED | ORAL | 72162-2488 |
Detailed information about Methocarbamol Tablets, Usp, 750 Mg
Methocarbamol is a central nervous system (CNS) depressant used as a skeletal muscle relaxant to treat acute musculoskeletal pain. It is typically prescribed as an adjunct to rest and physical therapy for short-term relief.
For the treatment of acute musculoskeletal conditions, the typical adult dosing regimen is designed to achieve rapid symptom control followed by a maintenance phase.
For the IV/IM formulation in severe cases, the usual dose is 1 gram (10 mL) to 3 grams (30 mL) daily for no more than three consecutive days.
Methocarbamol is generally not recommended for use in pediatric patients under the age of 16, except for the management of tetanus. In cases of tetanus, the pediatric dose is typically based on body weight (e.g., 15 mg/kg every 6 hours) and must be administered under strict medical supervision in a hospital setting. Safety and efficacy for routine musculoskeletal conditions in children have not been established.
Caution is advised when using the injectable form of methocarbamol in patients with impaired renal function. The vehicle (polyethylene glycol 300) can increase urea and creatinine levels and may potentially worsen pre-existing kidney damage. Oral tablets do not contain this vehicle but should still be used with caution as the drug is primarily excreted renally.
In patients with cirrhosis or significant liver disease, the metabolism of methocarbamol may be significantly slowed. This can lead to an increased half-life and higher plasma concentrations. Healthcare providers may recommend lower doses or longer intervals between doses for these patients.
Geriatric patients are often more sensitive to the sedative effects of methocarbamol. Because of the increased risk of falls and cognitive impairment, the American Geriatrics Society (Beers Criteria) suggests avoiding muscle relaxants in the elderly. If used, the lowest effective dose should be initiated.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this increases the risk of excessive CNS depression and side effects.
An overdose of methocarbamol can be life-threatening, especially when combined with alcohol or other CNS depressants. Symptoms of overdose include:
In the event of a suspected overdose, contact emergency medical services or a poison control center immediately. Treatment typically involves supportive care, gastric lavage (if caught early), and monitoring of vital signs.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the medication prematurely without medical guidance.
Because methocarbamol acts as a central nervous system depressant, the most frequent side effects are related to sedation. Approximately 10-15% of patients may experience:
These effects may occur in a smaller percentage of the population but are still frequently reported:
Methocarbamol is a potent CNS depressant. Patients must be aware that this medication can significantly impair mental and physical abilities. It should only be used for the short-term treatment of acute musculoskeletal pain and is not intended for chronic, long-term management of muscle disorders.
No FDA black box warnings for Methocarbamol.
There are no absolute drug-drug contraindications listed by the FDA that require complete avoidance; however, the combination with alcohol is considered highly dangerous and should be avoided due to the risk of fatal respiratory depression.
Methocarbamol is strictly contraindicated in the following scenarios:
These conditions require a careful risk-benefit analysis by a healthcare provider:
Methocarbamol is classified as Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. However, there have been rare reports of fetal abnormalities following in utero exposure to methocarbamol. Because the drug crosses the placental barrier, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally avoided during the first trimester.
It is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in breast milk, caution should be exercised when methocarbamol is administered to a nursing woman. The potential for sedation in the infant should be considered. If use is necessary, the infant should be monitored for excessive sleepiness or poor feeding.
Safety and effectiveness in pediatric patients below the age of 16 have not been established, except in the treatment of tetanus. For musculoskeletal pain, methocarbamol is not recommended for children due to the lack of clinical data and the potential for significant CNS depression.
Methocarbamol is a central nervous system (CNS) depressant with sedative and skeletal muscle relaxant properties. Its molecular mechanism does not involve direct action on the muscle fibers or the motor end plate. Instead, it is thought to act on the spinal cord and subcortical levels of the brain to inhibit polysynaptic reflex arcs. These arcs are responsible for maintaining muscle tone and responding to pain stimuli. By slowing the firing of these neurons, methocarbamol reduces the 'spasm-pain-spasm' cycle.
The onset of action for oral methocarbamol is typically within 30 minutes. The duration of effect lasts approximately 4 to 6 hours, which is why it is usually dosed four times daily. The drug does not produce significant changes in normal muscle tone or voluntary movement at therapeutic doses, focusing instead on pathologically increased muscle activity (spasms).
| Parameter | Value |
|---|---|
| Bioavailability | ~95% (Rapidly absorbed) |
Common questions about Methocarbamol Tablets, Usp, 750 Mg
Methocarbamol is primarily used for the short-term relief of muscle spasms and discomfort associated with acute musculoskeletal conditions, such as back pain, neck strains, or sports injuries. It is not used for chronic muscle diseases like cerebral palsy or multiple sclerosis. Healthcare providers typically prescribe it as an adjunct to rest, physical therapy, and other pain management strategies. The medication works by depressing the central nervous system rather than acting directly on the muscles. It is usually taken for a period of two to three weeks until the acute injury improves.
The most common side effects of methocarbamol include drowsiness, dizziness, and lightheadedness, which affect more than 10% of users. Some patients also report a metallic taste in their mouth, blurred vision, or mild nausea. Headaches and a feeling of 'fogginess' are also frequently documented during the first few days of treatment. Because it is a sedative, it can significantly impair your ability to perform tasks that require mental alertness. Most of these side effects are temporary and resolve once the medication is discontinued or the dose is adjusted by a doctor.
No, you should strictly avoid alcohol while taking methocarbamol. Both methocarbamol and alcohol are central nervous system depressants, and taking them together can lead to dangerous levels of sedation. This combination increases the risk of respiratory depression, where breathing becomes too shallow or stops entirely. It also significantly increases the risk of accidents, falls, and loss of consciousness. Even small amounts of alcohol can interact poorly with this medication, so it is best to wait until the drug is completely out of your system before consuming alcohol.
Methocarbamol is generally not recommended during pregnancy unless the potential benefits clearly outweigh the risks to the fetus. It is classified as Pregnancy Category C, meaning animal studies are lacking and there are no well-controlled human studies. There have been rare reports of birth defects associated with its use in the first trimester. The drug does cross the placenta and can affect the developing fetus's nervous system. If you are pregnant or planning to become pregnant, you must discuss safer alternatives for muscle pain with your healthcare provider.
Methocarbamol is absorbed quite rapidly by the body, with most patients feeling the effects within 30 minutes of taking an oral dose. Peak levels of the medication in the bloodstream are typically reached within one to two hours. Because it has a short half-life, the effects usually last for about four to six hours, which is why it is often prescribed to be taken four times a day. For severe spasms, a healthcare provider may start with a higher 'loading dose' for the first two or three days to achieve faster relief. If you do not feel relief within a few days, you should consult your doctor.
For most patients using methocarbamol for short-term acute pain, the medication can be stopped suddenly without significant withdrawal symptoms. Unlike benzodiazepines or certain other muscle relaxants, methocarbamol has a lower risk of physical dependence. However, if you have been taking high doses for an extended period, you should consult your doctor before stopping. They may suggest a gradual reduction to prevent a sudden return of muscle spasms. Always follow the specific duration of treatment prescribed by your healthcare provider to ensure the best outcome.
If you miss a dose of methocarbamol, take it as soon as you remember. If it is nearly time for your next dose, it is safer to skip the missed dose and continue with your regular schedule. Never take two doses at once to make up for a missed one, as this significantly increases the risk of excessive drowsiness and other side effects. Maintaining a consistent schedule helps keep the medication at an effective level in your body. If you frequently forget doses, consider using a pill reminder app or a weekly pill box.
Weight gain is not a commonly reported side effect of methocarbamol. Clinical trials and post-marketing surveillance do not list weight changes as a standard adverse reaction to the drug. However, because the medication can cause drowsiness and lethargy, some patients might become less physically active while taking it, which could indirectly lead to minor weight changes over time. If you notice rapid or unusual weight gain while taking this medication, it is more likely related to another condition or medication. You should discuss any significant weight changes with your healthcare provider.
Methocarbamol can interact with several types of medications, particularly those that also cause sedation. It should be used with extreme caution alongside opioids, benzodiazepines, sleep aids, and certain antidepressants. There is also a specific interaction with medications used for Myasthenia Gravis, such as pyridostigmine, which can make those treatments less effective. Always provide your doctor and pharmacist with a full list of your current medications, including herbal supplements like Valerian or Kava. Your healthcare provider will check for these interactions to ensure your treatment plan is safe.
Yes, methocarbamol is widely available as a generic medication in both 500 mg and 750 mg tablet strengths. The generic version is bioequivalent to the brand-name drug Robaxin, meaning it contains the same active ingredient and works the same way in the body. Generic methocarbamol is typically much more affordable than the brand-name version and is covered by most insurance plans. Whether you take the brand or the generic, the safety precautions, dosage instructions, and potential side effects remain the same. Consult your pharmacist if you have questions about different manufacturers of the generic drug.
Other drugs with the same active ingredient (Methocarbamol)
> Warning: Stop taking Methocarbamol and call your doctor immediately if you experience any of these serious reactions.
While methocarbamol is intended for short-term use (usually no more than 2-3 weeks), prolonged use can lead to several issues:
No FDA black box warnings for Methocarbamol. However, it carries significant warnings regarding its use in patients with Myasthenia Gravis and the potential for severe CNS depression when combined with other substances.
Report any unusual symptoms to your healthcare provider. Monitoring for skin rashes or changes in heart rate is especially important during the first week of treatment.
For most patients taking oral methocarbamol for a short duration, routine lab monitoring is not required. However, for those on higher doses or with underlying health conditions, healthcare providers may monitor:
Patients should be strongly advised against driving, operating heavy machinery, or engaging in hazardous activities until they are certain that methocarbamol does not make them excessively drowsy or dizzy. The impairment of motor skills can be significant, even if the patient feels 'fine.'
Alcohol consumption must be avoided while taking methocarbamol. Alcohol significantly enhances the sedative effects of the drug, increasing the risk of respiratory depression, profound sedation, and accidental injury.
While methocarbamol does not typically require a slow taper after short-term use, patients who have been taking high doses for an extended period should consult their doctor before stopping. Abrupt discontinuation after long-term use could theoretically lead to rebound muscle tension or anxiety.
> Important: Discuss all your medical conditions, especially kidney disease or myasthenia gravis, with your healthcare provider before starting Methocarbamol.
Methocarbamol may interfere with certain clinical laboratory tests:
For each major interaction, the management strategy usually involves dose reduction of one or both agents and rigorous patient education regarding the signs of over-sedation.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.
While methocarbamol is a carbamate, there is no definitive evidence of cross-sensitivity with other carbamate-class drugs (like carisoprodol). However, patients who have had severe reactions to guaifenesin (the parent compound) should be monitored closely, as methocarbamol is structurally related.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney disease or neurological disorders, before prescribing Methocarbamol.
Clinical studies of methocarbamol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, in general, elderly patients are at higher risk for the sedative effects of CNS depressants. The risk of dizziness, confusion, and falls is significantly higher in this population. The American Geriatrics Society recommends avoiding the use of skeletal muscle relaxants in older adults due to these safety concerns.
In patients with renal impairment, the clearance of methocarbamol and its metabolites may be reduced. While the oral form is not strictly contraindicated, the IV form must be avoided due to the PEG 300 vehicle. For oral use, healthcare providers may suggest longer dosing intervals.
In patients with chronic hepatic disease (cirrhosis), the mean elimination half-life of methocarbamol can be prolonged by approximately 70%, and the clearance can be reduced by 40%. Dose adjustments are almost always necessary for patients with significant liver dysfunction.
> Important: Special populations require individualized medical assessment and frequent monitoring by a healthcare professional.
| Protein Binding | 46% - 50% |
| Half-life | 1.1 - 2.0 hours |
| Tmax | 1 - 2 hours |
| Metabolism | Hepatic (Dealkylation, Hydroxylation, Conjugation) |
| Excretion | Renal (90% as metabolites) |
Methocarbamol belongs to the therapeutic class of skeletal muscle relaxants, specifically the carbamate derivative sub-class. It is pharmacologically related to guaifenesin and mephenesin. It is often compared to other muscle relaxants like cyclobenzaprine (which is structurally related to tricyclic antidepressants) and carisoprodol (which is a Schedule IV controlled substance).